Global burden and cross-country inequalities in six major immune-mediated inflammatory diseases from 1990 to 2021: A systemic analysis of the Global Burden of Disease Study 2021

2024-9-11

Targeting ferroptosis in autoimmune diseases: Mechanisms and therapeutic prospects

2024-9-1

Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?

2024-9-1

Editorial Board

2024-9-1

Global incidence trends of autoimmune diseases from 1990 to 2021 and projections to 2050: A systemic analysis of the global burden of disease study 2021

2024-9-1

Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis

2024-9-1

The intervention of macrophages in progressive fibrosis characterizing systemic sclerosis: A systematic review

2024-9-1

TO SHOw how we have been ENgaged in the APS FiELD (What we learned on APS collaborating with Professor Yehuda Shoenfeld)

2024-8-1

Cardiovascular disease in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis of observational studies

2024-8-1

The effects of lifestyle interventions on disease activity and quality of life in patients with systemic lupus erythematosus: A systematic review

2024-8-1

Ear abnormalities in chronic fatigue syndrome (CFS), fibromyalgia (FM), Coronavirus-19 infectious disease (COVID) and long-COVID syndrome (PCS), sick-building syndrome (SBS), post-orthostatic tachycardia syndrome (PoTS), and autoimmune/inflammatory syndrome induced by adjuvants (ASIA): A systematic review

2024-8-1

Are the new 2023 ACR/EULAR classification criteria suitable for advancing the knowledge of obstetric antiphospholipid syndrome?

2024-8-1

The role of microbiota and oxidative stress axis and the impact of intravenous immunoglobulin in systemic lupus erythematosus

2024-8-1

Issues in autoantibody tests used in the classification criteria for autoimmune rheumatic diseases: the laboratory autoimmunologist's perspective

2024-8-1

Early skeletal muscle manifestations in polyarteritis nodosa and ANCA-associated vasculitis

2024-8-1

B and T cells: (Still) the dominant orchestrators in autoimmune hepatitis

2024-8-1

Auto-immuno-deficiency syndromes

2024-8-1

Navigating the landscape of SLE treatment: An expert viewpoint on the rationality and limitations of early biologic intervention

2024-8-1

Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms

2024-8-1

Predicting autoimmune diseases: A comprehensive review of classic biomarkers and advances in artificial intelligence

2024-8-1

Helminth derivative tuftsin-phopshorylcholine, to treat autoimmunity

2024-8-1

Reflecting on a decade of the international consensus on ANA patterns (ICAP): Accomplishments and challenges from the perspective of the 7th ICAP workshop

2024-8-1

Immune thrombocytopenia (ITP) - could it be part of autoimmune/inflammatory syndrome induced by adjuvants (ASIA)?

2024-8-1

Unraveling the global burden of inflammatory bowel disease (1990–2019): A Joinpoint regression analysis of divergent trends in 10–24 and 50–69 age cohorts

2024-7-1

Global prevalence of obesity in patients with psoriasis: An analysis in the past two decades

2024-7-1

The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials

2024-7-1

Relapses in giant cell arteritis: Updated review for clinical practice

2024-7-1

Research Progress in pathogenesis of connective tissue disease-associated interstitial lung disease from the perspective of pulmonary cells

2024-7-1

Amphibole asbestos as an environmental trigger for systemic autoimmune diseases

2024-7-1

Rituximab-induced cystoid macular edema in a patient with systemic lupus erythematosus: A case report and literature review

2024-7-1

Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus

2024-7-1

Editorial Board

2024-7-1

The role of mitochondrial dysfunction in kidney injury and disease

2024-6-1

Efferocytosis: Unveiling its potential in autoimmune disease and treatment strategies

2024-6-1

Cardiovascular and cerebrovascular outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis: A systematic review with meta-analysis

2024-6-1

Practical guidance for the early recognition and follow-up of patients with connective tissue diseaserelated interstitial lung disease

2024-6-1

Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy

2024-6-1

Biological markers of high risk of thrombotic recurrence in patients with antiphospholipid syndrome: A literature review

2024-6-1

Exposome: Epigenetics and autoimmune diseases

2024-6-1

Remodeling of T-cell mitochondrial metabolism to treat autoimmune diseases

2024-6-1

Current evidence on the role of fibroblasts in large-vessel vasculitides: From pathogenesis to therapeutics

2024-6-1

Editorial Board

2024-6-1

Factors associated with incident cardiovascular disease in patients with rheumatoid arthritis: A scoping review

2024-5-1

Prevalence of anti-Ro52-kDa/SSA (TRIM21) antibodies and associated clinical phenotype in systemic sclerosis: Data from a French cohort, a systematic review and meta-analysis

2024-5-1

Twenty shades of the mosaic of autoimmunity

2024-5-1

The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus

2024-5-1

From autoantibody test results to decision making: Incorporating likelihood ratios within medical practice

2024-5-1

Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases

2024-5-1

Editorial Board

2024-5-1

The ‘whole landscape’ of research on systemic sclerosis over the past 73 years

2024-5-1